PULMONX CORPORATION Payments to Acquire Debt Securities, Available-for-sale
PULMONX CORPORATION (LUNG) reported Payments to Acquire Debt Securities, Available-for-sale of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-04
- PULMONX CORPORATION payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- PULMONX CORPORATION payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- PULMONX CORPORATION payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- PULMONX CORPORATION payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- PULMONX CORPORATION payments to acquire debt securities, available-for-sale for fiscal 2025 was $5.65M, a 79.76% decline from fiscal 2024.
- PULMONX CORPORATION payments to acquire debt securities, available-for-sale for fiscal 2024 was $27.91M, a 39.58% decline from fiscal 2023.
- PULMONX CORPORATION payments to acquire debt securities, available-for-sale for fiscal 2023 was $46.20M, a 2.09% decline from fiscal 2022.
- PULMONX CORPORATION payments to acquire debt securities, available-for-sale for fiscal 2022 was $47.19M, a 10.26% decline from fiscal 2021.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $0.00 10-Q · filed 2026-08-04 | $0.00 derived: sum of 3 quarters · filed 2026-08-04 | $0.00 derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-04 | $0.00 derived: sum of 2 quarters · filed 2026-05-04 | $0.00 derived: sum of 3 quarters · filed 2026-05-04 | $1.73M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $0.00 derived: sum of 2 quarters · filed 2026-03-10 | $1.73M derived: sum of 3 quarters · filed 2026-08-04 | $5.65M 10-K · filed 2026-03-10 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $1.73M derived: sum of 2 quarters · filed 2026-08-04 | $5.65M 10-Q · filed 2025-11-12 | $7.14M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $1.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $5.65M 10-Q · filed 2026-08-04 | $7.14M derived: sum of 3 quarters · filed 2026-08-04 | $12.73M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $3.92M 10-Q · filed 2026-05-04 | $5.42M derived: sum of 2 quarters · filed 2026-05-04 | $11.00M derived: sum of 3 quarters · filed 2026-05-04 | $18.03M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $1.49M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $7.08M derived: sum of 2 quarters · filed 2026-03-10 | $14.11M derived: sum of 3 quarters · filed 2026-03-10 | $27.91M 10-K · filed 2026-03-10 |
| 2024-09-30 | $5.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $12.61M derived: sum of 2 quarters · filed 2025-11-12 | $26.42M 10-Q · filed 2025-11-12 | $31.23M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $7.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-01 | $20.84M 10-Q · filed 2025-08-01 | $25.64M derived: sum of 3 quarters · filed 2025-08-01 | $41.41M derived: sum of 4 quarters · filed 2025-08-01 |
| 2024-03-31 | $13.81M 10-Q · filed 2025-05-02 | $18.61M derived: sum of 2 quarters · filed 2025-05-02 | $34.38M derived: sum of 3 quarters · filed 2025-05-02 | $46.89M derived: sum of 4 quarters · filed 2025-05-02 |
| 2023-12-31 | $4.80M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $20.58M derived: sum of 2 quarters · filed 2025-02-25 | $33.09M derived: sum of 3 quarters · filed 2025-02-25 | $46.20M 10-K · filed 2025-02-25 |
| 2023-09-30 | $15.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-01 | $28.28M derived: sum of 2 quarters · filed 2024-11-01 | $41.40M 10-Q · filed 2024-11-01 | $51.70M derived: sum of 4 quarters · filed 2024-11-01 |
| 2023-06-30 | $12.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-02 | $25.62M 10-Q · filed 2024-08-02 | $35.92M derived: sum of 3 quarters · filed 2024-08-02 | $50.85M derived: sum of 4 quarters · filed 2024-08-02 |
| 2023-03-31 | $13.12M 10-Q · filed 2024-05-03 | $23.42M derived: sum of 2 quarters · filed 2024-05-03 | $38.34M derived: sum of 3 quarters · filed 2024-05-03 | $50.99M derived: sum of 4 quarters · filed 2024-05-03 |
| 2022-12-31 | $10.30M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $25.23M derived: sum of 2 quarters · filed 2024-02-27 | $37.88M derived: sum of 3 quarters · filed 2024-02-27 | $47.19M 10-K · filed 2024-02-27 |
| 2022-09-30 | $14.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $27.58M derived: sum of 2 quarters · filed 2023-11-03 | $36.89M 10-Q · filed 2023-11-03 | $67.86M derived: sum of 4 quarters · filed 2023-11-03 |
| 2022-06-30 | $12.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | $21.96M 10-Q · filed 2023-08-04 | $52.94M derived: sum of 3 quarters · filed 2023-08-04 | $59.23M derived: sum of 4 quarters · filed 2023-08-04 |
| 2022-03-31 | $9.31M 10-Q · filed 2023-05-08 | $40.28M derived: sum of 2 quarters · filed 2023-05-08 | $46.58M derived: sum of 3 quarters · filed 2023-05-08 | $49.60M derived: sum of 4 quarters · filed 2023-05-08 |
| 2021-12-31 | $30.98M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $37.27M derived: sum of 2 quarters · filed 2023-03-01 | $40.30M derived: sum of 3 quarters · filed 2023-03-01 | $52.58M 10-K · filed 2023-03-01 |
| 2021-09-30 | $6.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $9.32M derived: sum of 2 quarters · filed 2022-11-08 | $21.61M 10-Q · filed 2022-11-08 | $21.61M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $3.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $15.31M 10-Q · filed 2022-08-08 | $15.31M derived: sum of 3 quarters · filed 2022-08-08 | $15.31M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $12.29M 10-Q · filed 2022-05-09 | $12.29M derived: sum of 2 quarters · filed 2022-05-09 | $12.29M derived: sum of 3 quarters · filed 2022-05-09 | $12.29M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $0.00 derived: sum of 2 quarters · filed 2022-03-01 | $0.00 derived: sum of 3 quarters · filed 2022-03-01 | $0.00 10-K · filed 2022-03-01 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $0.00 derived: sum of 2 quarters · filed 2021-11-09 | $0.00 10-Q · filed 2021-11-09 | $2.48M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $0.00 10-Q · filed 2021-08-10 | $2.48M derived: sum of 3 quarters · filed 2021-08-10 | |
| 2020-03-31 | $0.00 10-Q · filed 2021-05-12 | $2.48M derived: sum of 2 quarters · filed 2021-05-12 | ||
| 2019-12-31 | $2.48M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-15 | $21.45M 10-K · filed 2021-03-15 | ||
| 2019-09-30 | $18.97M 10-Q · filed 2020-11-13 | |||
| 2018-12-31 | $0.00 10-K · filed 2021-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SkinHealth Systems Inc. (SKIN) | United States | $0.086B | -3.17 |
| LENSAR, Inc. (LNSR) | United States | $0.087B | 2.02 |
| RenovoRx, Inc. (RNXT) | United States | $0.076B | -3.62 |
| Microbot Medical Inc. (MBOT) | $0.089B | -7.97 | |
| FRACTYL HEALTH, INC. (GUTS) | United States | $0.075B | -1.18 |
| CVRx, Inc. (CVRX) | United States | $0.067B | -2.62 |
| DarioHealth Corp. (DRIO) | $0.066B | -1.39 | |
| TELA Bio, Inc. (TELA) | United States | $0.057B | -0.82 |
| Xtant Medical Holdings, Inc. (XTNT) | United States | $0.053B | |
| Spectral AI, Inc. (MDAI) | United States | $0.052B |